Chronomodulated delivery schedule of oxaliplatin, 5 fluorouracil and folinic acid (FFL4/10) as first line treatment in metastatic colorectal cancer: Preliminary data of a phase II study

Gastric cancer is often diagnosed in locally advanced or metastatic stages and, therefore, of poor prognosis. Many controversies exist about surgery, neoadjuvant, adjuvant and palliative treatments of gastric cancer. So we need to explore a variety of novel management options including the use of new agents and new combinations. Some of these agents include oral fluoropyrimidine, irinotecan, docetaxel and oxaliplatin. Oxaliplatin is a diaminocyclohexane-platinum compound that is significantly different from cisplatin and carboplatin with respect to its activity and toxicity. Oxaliplatin is an alkylating agent inhibiting DNA replication by forming adducts between two adjacent guanines or guanine and adenine molecules. However, the adducts of oxaliplatin appear to be more effective than cisplatin adducts in regard to the inhibition of DNA synthesis. In contrast to cisplatin, oxaliplatin has demonstrated efficacy alone and in combination with 5-fluorouracil in advanced colorectal cancer. Many studies are ongoing to test the combination in noncolorectal gastrointestinal tumors and other malignancies. This review focuses on the increasing amount of data concerning the clinical activity of oxaliplatin-based regimens in advanced gastric cancer.

show abstract

The Emerging Role of Oxaliplatin in the Treatment of Gastric Cancer

Zaniboni

Meriggi²

2005

Journal of Chemotherapy

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Chronomodulated delivery schedule of oxaliplatin, 5 fluorouracil and folinic acid (FFL4/10) as first line treatment in metastatic colorectal cancer: Preliminary data of a phase II study

Cited by 1 publication

References 0 publications

The Emerging Role of Oxaliplatin in the Treatment of Gastric Cancer

The Emerging Role of Oxaliplatin in the Treatment of Gastric Cancer

Contact Info

Product

Resources

About